Sensorimotor Block Dynamics and Hemidiaphragmatic Palsy: Selective Trunk Block vs Supraclavicular Brachial Plexus Block
Launched by CHINESE UNIVERSITY OF HONG KONG · Dec 5, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of providing anesthesia for surgeries on the upper arm and hand. Researchers want to compare the effectiveness of a technique called selective trunk block (SeTB) to a more commonly used method known as supraclavicular brachial plexus block (BPB). They believe that SeTB may do a better job of numbing the entire arm, from the shoulder down to the hand, without causing certain side effects that can occur with the BPB method.
To participate in this trial, individuals aged between 18 and 75 who are scheduled for either elective or emergency surgery on their upper extremity may be eligible. However, some people may not qualify if they are pregnant, have certain skin infections, or have specific health issues such as respiratory problems or an allergy to local anesthesia. Participants can expect to receive either of the two anesthesia techniques during their surgery, and the study aims to gather important information on how well each technique works. Overall, this research could help improve pain management for future patients undergoing similar surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA 1-3 patients
- • Undergoing elective or emergency upper extremity surgery involving anywhere from the proximal humerus to distal hand or surgery involving any combination of these regions
- Exclusion Criteria:
- • Patient refusal
- • Pregnancy
- • Skin infection at the site of block placement
- • History of allergy to local anaesthetic (LA) drugs
- • Bleeding tendency or with evidence of coagulopathy
- • Pre-existing respiratory disease
- • Neurological deficit or neuromuscular disease.
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Manoj K Karmakar, MD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials